echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > 61% of patients achieve complete remission, FDA approves the first polycythemia vera interferon drug

    61% of patients achieve complete remission, FDA approves the first polycythemia vera interferon drug

    • Last Update: 2021-12-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, PharmaEssentia announced that the US FDA has approved the long-acting interferon Besremi (ropeginterferonα-2b-njft) to be marketed for the treatment of adult patients with polycythemia vera (PV)


    This approval is based on positive efficacy and safety data obtained in a phase 3 clinical trial


    Polycythemia vera is a rare, chronic and fatal blood cancer


    Besremi is an innovative monoformylated, long-acting interferon


    Reference materials:

    [1] US FDA Approves Besremi® (ropeginterferon alfa-2b-njft) as the Only Interferon for Adults With Polycythemia Vera.


    (The original text has been deleted)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.